Partners & Sponsors

IPM has partnered with a variety of institutions to advance the dapivirine ring from concept to late-stage clinical trials in just seven years, each bringing complementary resources and scientific ingenuity to the ring licensure program:

Microbicide Trials Network (MTN):  Funded by the US National Institutes of Health, MTN is a worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV. Given the dapivirine ring’s promise as a microbicide, MTN has partnered with IPM to advance the dapivirine ring licensure program and conduct the ASPIRE study. MTN will provide a list of its research centre sites when the study launches later this year.

Research center partners: IPM partners with local research centers in Africa to conduct clinical studies.  The following research centers are now participating in The Ring Study:

Janssen R&D Ireland:  IPM is developing dapivirine for use as a microbicide through a royalty-free licensing agreement with Janssen R&D Ireland (previously Tibotec Pharmaceutials), one of the Janssen pharmaceutical companies of Johnson & Johnson.

QPharma: A Sweden-based contract developer and pharmaceuticals manufacturer with 35 years experience, QPharma is manufacturing the dapivirine vaginal rings for the licensure program using highly specialized equipment.

Donors:  IPM’s work to date has been supported by governments, foundations, and multilateral organizations including: Belgium, Canada, Denmark, France, Germany, Ireland, Netherlands, Norway, Spain, Sweden, the United Kingdom and the United States; the European Commission, the World Bank, UNFPA, the Bill & Melinda Gates Foundation, the Rockefeller Foundation, the OPEC Fund for International Development, and the MAC AIDS Fund. View IPM’s donor list.

See all IPM partners.